skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The role of rasagiline in the treatment of Parkinson’s disease

Review

(3182) Views  (1051) Full article downloads

Authors: Julie Leegwater-Kim, Elena Bortan

Published Date May 2010 Volume 2010:5 Pages 149 - 156
DOI: http://dx.doi.org/10.2147/CIA.S4145

Julie Leegwater-Kim1, Elena Bortan2

1Tufts University School of Medicine and Department of Neurology, Lahey Clinic, Burlington, MA, USA; 2Department of Neurology, Lahey Clinic, Burlington, MA, USA

Abstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.

Keywords: rasagiline, monoamine oxidase inhibitor, Parkinson’s disease








Readers of this article also read:

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
Role of rasagiline in treating Parkinson’s disease: effect on disease progression
Potential antidiabetic and antioxidant activities of Morus indica and Asystasia gangetica in alloxan-induced diabetes mellitus
Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease
Antithrombotic therapy in very elderly patients with atrial fibrillation: Is it enough to assess thromboembolic risk?
Update on the management of constipation in the elderly: new treatment options
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
Testing the generalizability of national reimbursement rates with respect to local setting: the costs of abdominal aortic aneurysm surgery in Denmark
Association between depression and development of coronary artery disease: pathophysiologic and diagnostic implications